4Tech has appointed Michael Ennen as president and chief executive officer, effective immediately. Ennen succeeds co-founder Carine Schorochoff, who will continue to serve 4Tech as an advisor and board observer.
According to a company release, Ennen has more than 16 years of experience advancing early-stage medical devices and leading commercialisation of breakthrough technologies. Most recently, Ennen served as vice president and general manager of Interventional Products at Thoratec prior to its acquisition by St Jude Medical.
“I am delighted to welcome Mike to 4Tech as president and chief executive officer… Mike brings deep cardiovascular expertise to the role, as well as tremendous leadership, insight and passion,” says Bill Hawkins, chairman of the Board of Directors.
“I am honoured to be joining 4Tech, which I believe is positioned to create the category-defining percutaneous solution for tricuspid valve disease,” says Ennen.
Ennen previously served as chief scientific officer, vice president of Strategic Marketing, and vice president of Global Marketing at ev3/Covidien and Foxhollow Technologies. His background also includes roles as a commercial operations executive at TPG Capital/Immucor and as a leader of McKinsey & Company’s healthcare practice. Ennen earned his medical degree from Stanford University School of Medicine (Stanford, USA).
